Effect of Rituximab on Neurofilament Levels in <scp>CIDP</scp> : Results From the <scp>CIDPRIT</scp> Randomized Trial

The analysis did not demonstrate biomarker-based evidence of rituximab efficacy in CIDP. However, observed trends suggest a possible biological effect in reducing axonal injury in a subset of patients. Further studies are needed to clarify the role of sNfL in treatment monitoring and patient stratification.